Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer.
AR-prostate cancer
CRPC
anti-cancer agent
combination therapy
curcumin derivative
orthotopic model
raloxifene
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
05 Apr 2022
05 Apr 2022
Historique:
received:
15
03
2022
revised:
01
04
2022
accepted:
01
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Androgen receptor (AR)-castrate-resistant prostate cancer (CRPC) is an aggressive form of prostate cancer that does not have clinically approved targeted treatment options. To this end, the cytotoxic potential of raloxifene and the synthetic curcumin derivative 2,6-bis (pyridin-4-ylmethylene)-cyclohexanone (RL91) was examined in AR-(PC3 and DU145) cells and AR+ (LnCaP) CRPC cells. The results showed that both raloxifene and RL91 elicited significant cytotoxicity across three cell lines with the lowest EC
Identifiants
pubmed: 35453603
pii: biomedicines10040853
doi: 10.3390/biomedicines10040853
pmc: PMC9033055
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Otago Medical Research Foundation
ID : CT304 and LA325
Références
Life Sci. 2008 Apr 23;82(17-18):943-8
pubmed: 18371987
Nat Med. 2001 May;7(5):584-90
pubmed: 11329060
EJIFCC. 2014 Apr 28;25(1):42-54
pubmed: 27683456
Oncol Rep. 2010 Sep;24(3):779-85
pubmed: 20664987
Cancer Res. 2002 Sep 15;62(18):5365-9
pubmed: 12235008
Artif Intell Med. 2010 Nov;50(3):163-73
pubmed: 20620035
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
J Hematol Oncol. 2011 Apr 23;4:18
pubmed: 21513551
Breast Cancer Res Treat. 2010 Apr;120(3):557-65
pubmed: 19434490
J Biol Chem. 2007 Feb 9;282(6):3571-83
pubmed: 17148458
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Invest New Drugs. 2011 Feb;29(1):87-97
pubmed: 19816657
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
pubmed: 2359136
Ann Oncol. 2011 Nov;22(11):2476-2481
pubmed: 21436186
Prostate. 2018 Jan;78(1):2-10
pubmed: 29094395
Oncol Lett. 2015 Oct;10(4):2142-2148
pubmed: 26622809
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Biol Pharm Bull. 2006 Jul;29(7):1476-9
pubmed: 16819192
Prostate Cancer Prostatic Dis. 2005;8(2):108-18
pubmed: 15724144
Biol Reprod. 2009 Aug;81(2):378-87
pubmed: 19420388
Oncol Lett. 2018 May;15(5):6063-6076
pubmed: 29616091
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Expert Rev Endocrinol Metab. 2010 Nov;5(6):905-910
pubmed: 30780823
Cancer Treat Rev. 2019 Mar;74:35-42
pubmed: 30738364
J Cell Physiol. 2010 Jul;224(1):28-32
pubmed: 20301197
Drug Metab Dispos. 2008 Aug;36(8):1594-605
pubmed: 18480186
Am J Pathol. 1999 Aug;155(2):641-7
pubmed: 10433957
Oncogene. 2013 May 9;32(19):2390-402
pubmed: 22751110
Aging Male. 2018 Sep;21(3):211-222
pubmed: 29316844
Clin Transl Med. 2012 Oct 13;1(1):24
pubmed: 23369170
Cancer Res. 2000 Jun 15;60(12):3175-82
pubmed: 10866308
Pharmacogenomics. 2013 Apr;14(5):451-4
pubmed: 23556441
Oncogene. 2004 Jan 22;23(3):786-94
pubmed: 14737113
Clin Cancer Res. 2019 Apr 1;25(7):2072-2079
pubmed: 30635336
Mol Pharm. 2017 Jul 3;14(7):2368-2377
pubmed: 28597653